JP7044726B2 - グルコース依存性ミトコンドリア呼吸及び二相インスリン分泌応答を示すヒト多能性幹細胞由来の機能的ベータ細胞の生成 - Google Patents

グルコース依存性ミトコンドリア呼吸及び二相インスリン分泌応答を示すヒト多能性幹細胞由来の機能的ベータ細胞の生成 Download PDF

Info

Publication number
JP7044726B2
JP7044726B2 JP2018566957A JP2018566957A JP7044726B2 JP 7044726 B2 JP7044726 B2 JP 7044726B2 JP 2018566957 A JP2018566957 A JP 2018566957A JP 2018566957 A JP2018566957 A JP 2018566957A JP 7044726 B2 JP7044726 B2 JP 7044726B2
Authority
JP
Japan
Prior art keywords
cells
stage
cell
glucose
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018566957A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019518465A (ja
JP2019518465A5 (enExample
Inventor
リエック，セバスチャン
レザニア，アリレザ
Original Assignee
ヤンセン バイオテツク，インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク，インコーポレーテツド filed Critical ヤンセン バイオテツク，インコーポレーテツド
Publication of JP2019518465A publication Critical patent/JP2019518465A/ja
Publication of JP2019518465A5 publication Critical patent/JP2019518465A5/ja
Priority to JP2021196949A priority Critical patent/JP7429680B2/ja
Application granted granted Critical
Publication of JP7044726B2 publication Critical patent/JP7044726B2/ja
Priority to JP2023173813A priority patent/JP2024012312A/ja
Priority to JP2025072068A priority patent/JP2025121937A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0678—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M27/00—Means for mixing, agitating or circulating fluids in the vessel
    • C12M27/10—Rotating vessel
    • C12M27/12—Roller bottles; Roller tubes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0679—Cells of the gastro-intestinal tract
    • C12N5/068—Stem cells; Progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/335—Glucagon; Glucagon-like peptide [GLP]; Exendin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/345—Gastrin; Cholecystokinins [CCK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/375—Thyroid stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/395—Thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Sustainable Development (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018566957A 2016-06-21 2017-06-14 グルコース依存性ミトコンドリア呼吸及び二相インスリン分泌応答を示すヒト多能性幹細胞由来の機能的ベータ細胞の生成 Active JP7044726B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021196949A JP7429680B2 (ja) 2016-06-21 2021-12-03 グルコース依存性ミトコンドリア呼吸及び二相インスリン分泌応答を示すヒト多能性幹細胞由来の機能的ベータ細胞の生成
JP2023173813A JP2024012312A (ja) 2016-06-21 2023-10-05 グルコース依存性ミトコンドリア呼吸及び二相インスリン分泌応答を示すヒト多能性幹細胞由来の機能的ベータ細胞の生成
JP2025072068A JP2025121937A (ja) 2016-06-21 2025-04-24 グルコース依存性ミトコンドリア呼吸及び二相インスリン分泌応答を示すヒト多能性幹細胞由来の機能的ベータ細胞の生成

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662352968P 2016-06-21 2016-06-21
US62/352,968 2016-06-21
PCT/US2017/037373 WO2017222879A1 (en) 2016-06-21 2017-06-14 Generation of human pluripotent stem cell derived functional beta cells showing a glucose-dependent mitochondrial respiration and two-phase insulin secretion response

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021196949A Division JP7429680B2 (ja) 2016-06-21 2021-12-03 グルコース依存性ミトコンドリア呼吸及び二相インスリン分泌応答を示すヒト多能性幹細胞由来の機能的ベータ細胞の生成

Publications (3)

Publication Number Publication Date
JP2019518465A JP2019518465A (ja) 2019-07-04
JP2019518465A5 JP2019518465A5 (enExample) 2020-07-27
JP7044726B2 true JP7044726B2 (ja) 2022-03-30

Family

ID=60659269

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018566957A Active JP7044726B2 (ja) 2016-06-21 2017-06-14 グルコース依存性ミトコンドリア呼吸及び二相インスリン分泌応答を示すヒト多能性幹細胞由来の機能的ベータ細胞の生成
JP2021196949A Active JP7429680B2 (ja) 2016-06-21 2021-12-03 グルコース依存性ミトコンドリア呼吸及び二相インスリン分泌応答を示すヒト多能性幹細胞由来の機能的ベータ細胞の生成
JP2023173813A Pending JP2024012312A (ja) 2016-06-21 2023-10-05 グルコース依存性ミトコンドリア呼吸及び二相インスリン分泌応答を示すヒト多能性幹細胞由来の機能的ベータ細胞の生成
JP2025072068A Pending JP2025121937A (ja) 2016-06-21 2025-04-24 グルコース依存性ミトコンドリア呼吸及び二相インスリン分泌応答を示すヒト多能性幹細胞由来の機能的ベータ細胞の生成

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021196949A Active JP7429680B2 (ja) 2016-06-21 2021-12-03 グルコース依存性ミトコンドリア呼吸及び二相インスリン分泌応答を示すヒト多能性幹細胞由来の機能的ベータ細胞の生成
JP2023173813A Pending JP2024012312A (ja) 2016-06-21 2023-10-05 グルコース依存性ミトコンドリア呼吸及び二相インスリン分泌応答を示すヒト多能性幹細胞由来の機能的ベータ細胞の生成
JP2025072068A Pending JP2025121937A (ja) 2016-06-21 2025-04-24 グルコース依存性ミトコンドリア呼吸及び二相インスリン分泌応答を示すヒト多能性幹細胞由来の機能的ベータ細胞の生成

Country Status (16)

Country Link
US (3) US10633635B2 (enExample)
EP (2) EP3472303B1 (enExample)
JP (4) JP7044726B2 (enExample)
KR (5) KR102376911B1 (enExample)
CN (2) CN109415693B (enExample)
AR (1) AR108847A1 (enExample)
AU (3) AU2017282638C1 (enExample)
CA (1) CA3027879A1 (enExample)
DK (1) DK3472303T3 (enExample)
ES (1) ES2939233T3 (enExample)
FI (1) FI4194548T3 (enExample)
MA (2) MA71715A (enExample)
RU (1) RU2752499C2 (enExample)
SG (1) SG11201810550WA (enExample)
TW (1) TW201809266A (enExample)
WO (1) WO2017222879A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL308120B2 (en) 2017-06-14 2024-12-01 Vertex Pharma Devices and methods for delivering therapeutics
AU2018330499B2 (en) * 2017-09-11 2025-01-30 Novo Nordisk A/S Enrichment of NKX6.1 and C-peptide co-expressing cells derived in vitro from stem cells
AU2018370029B2 (en) 2017-11-15 2024-11-07 Vertex Pharmaceuticals Incorporated Islet cell manufacturing compositions and methods of use
IL277025B2 (en) * 2018-03-02 2024-04-01 Vertex Pharma Methods of enhancing stem cell differentiation into beta cells
EP3786286A4 (en) * 2018-04-27 2022-01-26 Kaneka Corporation PRODUCTION PROCESS FOR PANCREATIC BETA CELLS
WO2019217493A2 (en) * 2018-05-07 2019-11-14 President And Fellows Of Harvard College Cell populations and gene expression associated with in vitro beta cell differentiation
US12421499B2 (en) 2018-05-11 2025-09-23 Cornell University Method of differentiation of human pluripotent stem cells to monohormonal cells
AU2019320072A1 (en) 2018-08-10 2021-02-25 Vertex Pharmaceuticals Incorporated Stem cell derived islet differentiation
CA3139585C (en) 2019-05-31 2024-01-23 W. L. Gore & Associates, Inc. A biocompatible membrane composite
AU2020283056B2 (en) 2019-05-31 2023-06-08 Viacyte, Inc. A biocompatible membrane composite
US20220234006A1 (en) 2019-05-31 2022-07-28 W. L. Gore & Associates, Inc. A biocompatible membrane composite
CA3139292C (en) 2019-05-31 2025-06-10 Viacyte, Inc. CELL ENCAPSULATION DEVICES WITH REGULATED OXYGEN DIFFUSION DISTANCES
CA3144948A1 (en) * 2019-06-25 2020-12-30 Vertex Pharmaceuticals Incorporated Enhanced differentiation of beta cells
WO2020264172A1 (en) * 2019-06-27 2020-12-30 Dana-Farber Cancer Institute, Inc. Compounds, compositions, and methods for protein degradation
CA3150233A1 (en) 2019-09-05 2021-03-11 Alireza Rezania Universal donor cells
US20230014430A1 (en) * 2019-11-20 2023-01-19 Washington University Methods and Compositions for Generating Functionally Mature Beta Cells and Uses Thereof
WO2021233116A1 (zh) * 2020-05-21 2021-11-25 北京大学 多能干细胞的成分明确、无异源的培养系统
EP4189067A4 (en) 2020-07-31 2024-10-23 Vertex Pharmaceuticals Incorporated DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS
AU2021414405A1 (en) 2020-12-31 2023-08-10 Crispr Therapeutics Ag Universal donor cells
CN114958726B (zh) * 2021-02-23 2025-03-21 海门雨霖细胞科技有限责任公司 化学诱导成纤维细胞重编程为肺干细胞的化学小分子组合物及其应用
US20240182864A1 (en) * 2021-03-24 2024-06-06 Salk Institute For Biological Studies Novel chemical combinations and methods of use thereof, towards differentiation of human progenitor cells into functional beta cells
WO2022236173A1 (en) * 2021-05-07 2022-11-10 Mayo Foundation For Medical Education And Research Treating liver disease
US20220403340A1 (en) * 2021-06-11 2022-12-22 Washington University Media for cryopreserved cells and methods of making and using same
AU2022377078A1 (en) 2021-11-01 2024-04-04 Vertex Pharmaceuticals Incorporated Stem cell derived pancreatic islet differentiation
CN114317401B (zh) * 2021-12-07 2022-10-04 浙江大学 一种促进胰岛前体细胞长期稳定传代的方法
KR102848180B1 (ko) * 2021-12-15 2025-08-19 한국화학연구원 오로라 키나아제 억제제를 이용하는 심근세포 및 심장 오가노이드의 제조방법
WO2025117331A1 (en) 2023-12-01 2025-06-05 Eli Lilly And Company Methods of making stem cell-derived islet-like cells, as well as populations and compositions including the same
WO2025119299A1 (en) * 2023-12-08 2025-06-12 Hangzhou Reprogenix Bioscience, Inc. Method for differentiating pancreatic beta cells
WO2025202874A1 (en) 2024-03-25 2025-10-02 Crispr Therapeutics Ag Genetically modified cells expressing glp-1 receptor agonist

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015002724A2 (en) 2013-06-11 2015-01-08 President And Fellows Of Harvard College SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME
JP2016506246A (ja) 2012-12-31 2016-03-03 ヤンセン バイオテツク，インコーポレーテツド 多能性幹細胞から膵臓内分泌細胞膵臓内分泌細胞への分化のための、空気−液体界面での、ヒト胚性幹細胞の培養

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
PL1641916T3 (pl) 2003-06-27 2016-08-31 Depuy Synthes Products Inc Regeneracja i naprawa tkanki nerwowej z wykorzystaniem komórek poporodowych
SG149061A1 (en) 2003-12-23 2009-01-29 Cythera Inc Definitive endoderm
WO2007059007A2 (en) * 2005-11-14 2007-05-24 Cythera, Inc. Markers of definitive endoderm
US20050266554A1 (en) 2004-04-27 2005-12-01 D Amour Kevin A PDX1 expressing endoderm
CN101589137B (zh) 2005-03-31 2013-06-05 斯丹姆涅恩有限公司 羊膜来源的细胞组合物及其制备方法和用途
AU2006202209B2 (en) 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
US7807459B2 (en) 2005-09-27 2010-10-05 Reneuron, Inc. EphA4-positive human adult pancreatic endocrine progenitor cells
US7695965B2 (en) 2006-03-02 2010-04-13 Cythera, Inc. Methods of producing pancreatic hormones
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
WO2008011518A2 (en) * 2006-07-19 2008-01-24 Diakine Therapeutics, Inc. Encapsulation system
AU2007277364B2 (en) 2006-07-26 2010-08-12 Viacyte, Inc. Methods of producing pancreatic hormones
CA2954431C (en) 2007-11-27 2021-08-24 Lifescan, Inc. Differentiation of human embryonic stem cells to pancreatic cells
US8338170B2 (en) 2008-04-21 2012-12-25 Viacyte, Inc. Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells
WO2009132083A2 (en) 2008-04-22 2009-10-29 President And Fellows Of Harvard College Compositions and methods for promoting the generation of pdx1+ pancreatic cells
EP2942392B1 (en) 2008-06-30 2018-10-03 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
RU2011103183A (ru) 2008-06-30 2012-08-10 Сентокор Орто Байотек Инк. (Us) Дифференцирование плюрипотентных стволовых клеток
MX2011004565A (es) * 2008-10-31 2011-07-28 Centocor Ortho Biotech Inc Diferenciacion de celulas madre embrionarias humanas al linaje endocrino pancreatico.
US8895300B2 (en) 2008-11-04 2014-11-25 Viacyte, Inc. Scalable primate pluripotent stem cell aggregate suspension culture and differentiation thereof
US8008075B2 (en) 2008-11-04 2011-08-30 Viacyte, Inc. Stem cell aggregate suspension compositions and methods of differentiation thereof
PL2494035T3 (pl) 2009-10-29 2018-07-31 Janssen Biotech, Inc. Pluripotencjalne komórki macierzyste
MX343786B (es) 2009-12-23 2016-11-22 Janssen Biotech Inc Diferenciacion de celulas madre embrionarias humanas.
NZ607608A (en) 2010-08-09 2014-03-28 Takeda Pharmaceuticals Co Method of producing pancreatic hormone-producing cells
MX2014007744A (es) * 2011-12-22 2015-01-12 Janssen Biotech Inc Diferenciacion de celulas madre embrionicas humanas en celulas individuales positivas de insulina hormonal.
DK3450542T3 (da) * 2012-06-08 2021-11-01 Janssen Biotech Inc Differentiering af humane embryonale stamceller til endokrine pancreatiske celler
WO2014033322A1 (en) 2012-09-03 2014-03-06 Novo Nordisk A/S Generation of pancreatic endoderm from pluripotent stem cells using small molecules
JP6316822B2 (ja) * 2012-12-26 2018-04-25 国立大学法人京都大学 膵外分泌細胞の誘導方法
ES2942484T3 (es) 2012-12-31 2023-06-01 Janssen Biotech Inc Diferenciación de células madre embrionarias humanas en células endocrinas pancreáticas usando reguladores de HB9
RU2687379C2 (ru) 2012-12-31 2019-05-13 Янссен Байотек, Инк. Суспендирование и кластеризация плюрипотентных клеток человека с целью их дифференцировки в панкреатические эндокринные клетки
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
US20140329704A1 (en) * 2013-03-28 2014-11-06 President And Fellows Of Harvard College Markers for mature beta-cells and methods of using the same
JP6588969B2 (ja) 2014-05-16 2019-10-09 ヤンセン バイオテツク，インコーポレーテツド 膵内分泌細胞内のｍａｆａ発現を強化するための小分子の使用
WO2017120543A1 (en) * 2016-01-08 2017-07-13 Massachusetts Institute Of Technology Production of differentiated enteroendocrine cells and insulin producing cells
MA45747A (fr) * 2016-02-24 2019-01-02 Novo Nordisk As Génération de cellules bêta fonctionnelles à partir de progéniteurs endocrines dérivés de cellules souhes pluripotentes humaines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016506246A (ja) 2012-12-31 2016-03-03 ヤンセン バイオテツク，インコーポレーテツド 多能性幹細胞から膵臓内分泌細胞膵臓内分泌細胞への分化のための、空気−液体界面での、ヒト胚性幹細胞の培養
WO2015002724A2 (en) 2013-06-11 2015-01-08 President And Fellows Of Harvard College SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EMBO J.，2014年，Vol. 33, No. 19，pp.2157-2170
Transplant. Proc.，2011年，Vol. 43，pp.3212-3216

Also Published As

Publication number Publication date
KR102607813B1 (ko) 2023-11-29
US10633635B2 (en) 2020-04-28
US20200208116A1 (en) 2020-07-02
EP3472303B1 (en) 2022-12-14
EP3472303A1 (en) 2019-04-24
JP2019518465A (ja) 2019-07-04
AR108847A1 (es) 2018-10-03
JP7429680B2 (ja) 2024-02-08
WO2017222879A1 (en) 2017-12-28
JP2025121937A (ja) 2025-08-20
JP2024012312A (ja) 2024-01-30
KR20220039833A (ko) 2022-03-29
RU2752499C2 (ru) 2021-07-28
US11952591B2 (en) 2024-04-09
EP4194548A1 (en) 2023-06-14
MA45502A (fr) 2019-04-24
AU2022291632A1 (en) 2023-02-02
AU2022291632B2 (en) 2025-05-01
EP3472303A4 (en) 2020-02-19
CA3027879A1 (en) 2017-12-28
KR20230011507A (ko) 2023-01-20
KR20190011268A (ko) 2019-02-01
FI4194548T3 (fi) 2025-12-31
TW201809266A (zh) 2018-03-16
KR20230169395A (ko) 2023-12-15
KR20250041196A (ko) 2025-03-25
AU2025208573A1 (en) 2025-08-21
CN109415693B (zh) 2023-03-21
SG11201810550WA (en) 2019-01-30
KR102489946B1 (ko) 2023-01-18
MA71715A (fr) 2025-05-30
EP4194548B1 (en) 2025-10-22
AU2017282638B2 (en) 2022-10-06
RU2019101200A3 (enExample) 2021-01-18
KR102785694B1 (ko) 2025-03-21
AU2017282638C1 (en) 2023-03-16
JP2022033900A (ja) 2022-03-02
DK3472303T3 (da) 2023-01-23
US20170362572A1 (en) 2017-12-21
CN109415693A (zh) 2019-03-01
AU2017282638A1 (en) 2018-12-06
US20240417693A1 (en) 2024-12-19
RU2019101200A (ru) 2020-07-21
KR102376911B1 (ko) 2022-03-18
ES2939233T3 (es) 2023-04-20
CN116286663A (zh) 2023-06-23

Similar Documents

Publication Publication Date Title
JP7044726B2 (ja) グルコース依存性ミトコンドリア呼吸及び二相インスリン分泌応答を示すヒト多能性幹細胞由来の機能的ベータ細胞の生成
AU2021203995B2 (en) Use of small molecules to enhance MAFA expression in pancreatic endocrine cells
RU2768963C2 (ru) Культивация эмбриональных стволовых клеток человека в воздушно-жидкостной зоне взаимодействия с целью их дифференцировки в панкреатические эндокринные клетки

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200611

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211203

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220308

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220317

R150 Certificate of patent or registration of utility model

Ref document number: 7044726

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250